SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is rallying as investors react to a strategic $14.2 billion deal to regain full ownership of its Ireland-based Fab 34, a move perceived as a major vote of confidence in the company's manufacturing and AI-driven growth trajectory. The community is actively debating the stock's future, with many interpreting the heavy capital reinvestment as a clear indicator that major new customer contracts are imminent.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is currently trending following news that it has secured FDA approval for VYKAT XR, the first therapy developed to treat hyperphagia in Prader-Willi syndrome. The community is actively discussing the stock's significant price momentum, debating the potential for a future acquisition by a larger pharmaceutical player, and evaluating the long-term commercial execution of this newly approved asset.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as the market reacts to the company's latest subscription price hikes, which analysts view as a strategic move to fund a massive content budget and solidify profitability. While some retail investors are voicing frustration over recurring cost increases, the community is heavily focused on the stock's relative strength and technical breakout potential, with many discussing its role as a hedge against broader market volatility.

“Buttcoin - The Next Bitcoin” is the memecoin version of Bitcoin. Launched on January 30, 2025, on Pump.fun, it’s a community-owned memecoin on Solana. The idea was inspired by a 4:20 minutes long YouTube video from 2013 called "The Next Bitcoin?" by James D. McMurray.

The Next Bitcoin

Investors are rallying behind this Solana-based meme coin as a satirical movement intended to mock established market structures, with community members actively comparing its long-term potential to industry giants. Discussions are currently dominated by enthusiasts promoting the token's cultural narrative and its goal of creating viral engagement within the broader crypto ecosystem.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is trending as the market reacts to the definitive agreement to acquire Soleno Therapeutics for $2.9 billion. Community sentiment is mixed, with active debate regarding whether the acquisition effectively addresses Neurocrine's need for pipeline growth or if the premium paid for the rare-disease asset signals a strategic overpay.

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group Inc.

Altria Group is seeing significant investor interest driven by a combination of resilient pricing power in its core smokeable business and ongoing momentum in its smoke-free portfolio, particularly with the growth of its on! nicotine pouches. The community is actively debating the company's long-term pivot from traditional cigarettes toward smoke-free alternatives, with many highlighting the stock's role as a classic, high-yield defensive play in a volatile market.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxis Precision Medicines is experiencing a significant surge in momentum as the company reports positive trial results for its essential tremor and epilepsy therapies, driving multiple analyst price target upgrades. While the community is debating the impact of a recent large-scale public offering, many investors remain bullish on the long-term potential of the company's CNS-focused pipeline.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is currently trending as shareholders analyze the strategic implications of parent company Centurium Capitals acquisition of Blue Bottle Coffee. While the community remains divided over potential conflicts of interest versus synergistic growth, investors are closely monitoring for signs of a long-anticipated U.S. exchange relisting and are actively debating the stock's future valuation amid shifting institutional ownership.

A2Z Cust2Mate Solutions Corp. is a technology company, which engages in the development and commercialization of retail smart cart solutions for large grocery stores and supermarkets. It operates through the Smart Carts and Precision Metal Parts segments. The Smart Carts segment offers retail automation solutions. Its platform enables seamless in-cart scanning and payment, allowing shoppers to bypass checkout lines while receiving real-time customized offers and product recommendations. The Precision Metal Parts segment includes the manufacturing and sale of precision metal parts. The company was founded by Joseph Bentsur on January 15, 2018 and is headquartered in Vancouver, Canada.

A2Z Cust2Mate Solutions Corp.

A2Z Smart Technologies Corp.

A2Z Smart Technologies is trending following a major five-year strategic agreement to deploy 4,000 smart shopping carts at Carrefour Israel, a move the community views as a significant model for global scalability. Investors are actively discussing the company's retail media expansion, potential for recurring revenue, and bullish technical setups, with many highlighting institutional interest from significant fund stakes as a vote of confidence in the stock's long-term growth trajectory.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is currently trending due to intense speculation surrounding a potential short squeeze, driven by extremely limited share availability for borrowing and surging borrow fees. The community is actively debating the stock's volatility, with many retail traders drawing comparisons to historical meme stock runs while critics emphasize the company's lack of revenue and potential for dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates

Aytu BioPharma (AYTU) delivered earnings and revenue surprises of -303.85% and +26.27%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Aytu BioPharma AYTU Q2 2026 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

New Strong Sell Stocks for February 2nd

AAWH, AYTU and BCAL have been added to the Zacks Rank #5 (Strong Sell) List on February 2, 2026.

Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates

Aytu BioPharma (AYTU) delivered earnings and revenue surprises of -33.33% and +10.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Insights into Aytu BioPharma's Upcoming Earnings

Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates

Astria Therapeutics (ATXS) delivered earnings and revenue surprises of -34.15% and -95.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates

Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -153.85% and +9.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for Oct. 13th

AYTU, ALK and CNM have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2025.

U.S. stocks appear set for a positive opening on Tuesday ahead of Federal Reserve Chair Jerome Powell’s speech as investors look for clues on the central bank’s direction on monetary policy going forward.While Dow Jones futures were up 0.13% at the time of writing, the S&amp;P 500 futures edged lower by 0.03%, while the tech-heavy Nasdaq 100’s futures rose 0.02%. Futures of the Russell 2000 index were up 0.04%.Meanwhile, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) was down 0.03% at the time of writing, while&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ) rose 0.02% on Tuesday morning. Retail sentiment around the S&amp;P 500 ETF on Stocktwits was in the ‘bullish’ territory.Asian markets ended Tuesday’s trading session on a mixed note, with the TWSE Capitalization Weighted Stock index gaining the most at 1.4%, followed by the KOSPI at 0.5%.The Shanghai Composite index declined 0.9%, while the Hang Seng index closed lower by 0.54%.The Nikkei 225 index was closed for trading due to the Autumnal Equinox.Stocks To Watch<ul><li>Boeing Co. (BA): Boeing shares were up nearly 3% in Tuesday’s pre-market session amid reports that the U.S. and China are in the final stages of negotiation for a “huge” deal for the company’s aircraft, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-23/us-china-talks-for-huge-boeing-aircraft-order-in-final-stages">report</a>.</li><li>MicroCloud Hologram Inc. (HOLO): MicroCloud shares continued to soar following an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/micro-cloud-hologram-stock-picks-up-momentum-after-near-wipeout-this-year/chDhN2vR3PS">announcement</a> by the company on Friday last week that it has developed a universal quantum probability theory to control the phase of quantum photonic states, which has applications across multiple domains. MicroCloud was the top trending ticker on the Stocktwits platform at the time of writing, with the stock up more than 20% in Tuesday’s pre-market session.</li><li>Better Home &amp; Finance Holding Co. (BETR): Better Home’s shares were up nearly 25% in Tuesday’s pre-market trade after hedge fund manager Eric Jackson&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/better-stock-rockets-as-opendoor-bull-eric-jackson-predicts-350x-gains/chDhKvgR3PI">disclosed</a> a position in the company on Monday.</li><li>Firefly Aerospace Inc. (FLY): Firefly Aerospace shares plunged nearly 10% pre-market after the company’s second-quarter (Q2) results missed Wall Street expectations. Firefly reported a loss of $5.78 per share on revenue of $15.55 million, while analysts expected a loss of $0.43 per share on revenue of $16.82 million, according to Stocktwits data.</li><li>CleanSpark Inc. (CLSK): CleanSpark shares surged more than 5% in Tuesday’s pre-market session after the Bitcoin mining company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-cleanspark-stock-rising-5-premarket/chDhoueR3Ps">secured</a> a new $100 million credit facility with Coinbase Prime.</li><li>Micron Technology Inc. (MU) and Aytu BioPharma Inc. (AYTU) are among the companies scheduled to announce their latest quarterly results on Tuesday.</li></ul>&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fed-musalem-limited-room-for-further-rate-cuts/chDQqpnR321">Fed's Musalem Says There's 'Limited Room' For Further Rate Cuts Without Policy Becoming Overly Accommodative</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

People walk by the New York Stock Exchange

Dow Futures Gain Ahead Of Jerome Powell’s Speech: BA, HOLO, BETR, CLSK Among Stocks To Watch

While Dow Jones futures were up 0.13% at the time of writing, the S&P 500 futures edged lower by 0.03%.

Equity

Agilent Technologies (A) Surpasses Q3 Earnings and Revenue Estimates

Agilent (A) delivered earnings and revenue surprises of +0.74% and +4.60%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Denver, CO.

Aytu BioPharma Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

AYTU
Aytu BioPharma Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest AYTU News

AYTUAytu BioPharma Inc